Sign up Australia
Proactive Investors - Run By Investors For Investors

Viralytics completes $27M institutional fund raising for melanoma clinical trials

Viralytics completes $27M institutional fund raising for melanoma clinical trials

Viralytics Limited (ASX:VLA, OTC:VRACY) has welcomed new institutional investors as part of its now completed $27.1 million capital raising, via issue of 97 million shares at $0.28.

The capital raised will fully fund the company through 2016 including its clinical trial programs.

Viralytics currently has a Phase 2 intratumoural trial in melanoma patients, and a Phase 1/2 intravenous trial in solid cancer types ongoing.

A randomised melanoma clinical trial is currently in development to evaluate Viralytics lead product CAVATAK in late-stage cancer patients.

Bell Potter Securities acted as the Lead Manager of the equity offering with Roth Capital Partners acting as the Sole US Placement Agent.

With this potentially transformational capital injection, Viralytics plans to generate new clinical data for CAVATAK across a number of cancer types.

Shares in the company last traded at $0.34, and is now capitalised at around $70 million.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

View full VLA profile View Profile

Viralytics Timeline

Newswire
December 10 2015

Related Articles

1538160791_petri-dishes.jpg
September 29 2018
The biotech group revealed it had brought in $9.1mln via an oversubscribed placing
lungs
September 25 2018
The drug developer had originally to recruit 80 people for the second part of its phase II study of its SNG001 treatment, but it will now assess 120 patients
syringe
June 21 2018
“FLU-v is designed to protect against a broad range of influenza viral strains and this includes unexpected seasonal strains or a potentially devastating pandemic strain"

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use